|Articles|June 27, 2011

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Linagliptin cardiovascular safety profile appears superior to glimepiride

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

Dolly Parton's health care legacy: Two decades of giving

The key tech components every primary care practice needs to deliver exceptional mental health services

At least 1 in 4 former NFL players had CTE at death; food logging tracks with weight loss; a cancer protein's second job — Morning Medical Update